Latest Sapien Valve Gets EU Go-Ahead, But Germany Will Have To Wait

Edwards Lifesciences plans a "controlled rollout" of its Sapien 3 Ultra transcatheter heart valve replacement in Europe following the CE mark announced Nov. 16. But a patent dispute with Boston Scientific will prevent Edwards from launching it in Germany.

More from Approvals

More from Policy & Regulation